{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:54:44Z","timestamp":1790924084019,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Edson Queiroz Foundation\/University of Fortaleza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-06226-5","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:06:26Z","timestamp":1783335986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["VCAM-1 as a biomarker of early cardiac phenotypic changes in Fabry disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Danielli Oliveira da Costa","family":"Lino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gdayllon Cavalcante","family":"Meneses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Moreira","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Maria Costa","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Jorge de Sousa","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Jos\u00e9 Mota","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Paulo de Sousa","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth De Francesco","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldo Bezerra","family":"da Silva Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"8","key":"6226_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/metabo12080703","volume":"12","author":"MT Rocchetti","year":"2022","unstructured":"Rocchetti MT, et al. Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects. Metabolites. 2022;12(8):703.","journal-title":"Metabolites"},{"key":"6226_CR2","first-page":"19","volume":"4","author":"G Serebrinsky","year":"2015","unstructured":"Serebrinsky G, et al. Late onset variants in Fabry disease: Results in high risk population screenings in Argentina. Mol Genet Metab Rep. 2015;4:19\u201324.","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"6226_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a KDIGO Controversies Conference. Kidney Int. 2017;91(2):284\u201393.","journal-title":"Kidney Int"},{"issue":"3","key":"6226_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122(3):19\u201327.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"6226_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"D Doheny","year":"2018","unstructured":"Doheny D, et al. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017. J Med Genet. 2018;55(4):261\u20138.","journal-title":"J Med Genet"},{"issue":"19","key":"6226_CR6","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.3390\/jcm13195953","volume":"13","author":"C Gatterer","year":"2024","unstructured":"Gatterer C, et al. NT-proBNP Reflects Left Ventricular Hypertrophy Rather than Left Ventricular Dilatation or Systolic Dysfunction in Patients with Fabry Disease. J Clin Med. 2024;13(19):5953.","journal-title":"J Clin Med"},{"issue":"12","key":"6226_CR7","doi-asserted-by":"publisher","first-page":"e009430","DOI":"10.1161\/CIRCIMAGING.119.009430","volume":"12","author":"S Nordin","year":"2019","unstructured":"Nordin S, et al. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy. Circ Cardiovasc Imaging. 2019;12(12):e009430.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"6226_CR8","doi-asserted-by":"publisher","first-page":"107585","DOI":"10.1016\/j.ymgme.2023.107585","volume":"139","author":"A Burlina","year":"2023","unstructured":"Burlina A, et al. An expert consensus on the recommendations for the use of biomarkers in Fabry disease. Mol Genet Metab. 2023;139(2):107585.","journal-title":"Mol Genet Metab"},{"issue":"21","key":"6226_CR9","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.3390\/ijms21218080","volume":"21","author":"I Simonetta","year":"2020","unstructured":"Simonetta I, et al. Biomarkers in Anderson-Fabry Disease. Int J Mol Sci. 2020;21(21):8080.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"6226_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/jcm10081664","volume":"10","author":"C Carnicer-Caceres","year":"2021","unstructured":"Carnicer-Caceres C, et al. Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up. J Clin Med. 2021;10(8):1664.","journal-title":"J Clin Med"},{"issue":"15","key":"6226_CR11","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.3390\/ijms25158273","volume":"25","author":"DC Faro","year":"2024","unstructured":"Faro DC, Di Pino FL, Monte IP, Inflammation. Oxidative Stress, and Endothelial Dysfunction in the Pathogenesis of Vascular Damage: Unraveling Novel Cardiovascular Risk Factors in Fabry Disease. Int J Mol Sci. 2024;25(15):8273.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6226_CR12","doi-asserted-by":"publisher","first-page":"e002839","DOI":"10.1161\/JAHA.115.002839","volume":"5","author":"N Seydelmann","year":"2016","unstructured":"Seydelmann N, et al. High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. J Am Heart Assoc. 2016;5(6):e002839.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"6226_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/diagnostics14020208","volume":"14","author":"A Iorio","year":"2024","unstructured":"Iorio A, et al. Anderson-Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement. Diagnostics (Basel). 2024;14(2):208.","journal-title":"Diagnostics (Basel)"},{"issue":"439","key":"6226_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1651-2227.2002.tb03112.x","volume":"91","author":"K Demuth","year":"2002","unstructured":"Demuth K, Germain DP. Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl. 2002;91(439):57\u201361.","journal-title":"Acta Paediatr Suppl"},{"issue":"5","key":"6226_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0003319720981521","volume":"72","author":"AC Vujkovac","year":"2021","unstructured":"Vujkovac AC, et al. Characteristics of Vascular Phenotype in Fabry Patients. Angiology. 2021;72(5):426\u201333.","journal-title":"Angiology"},{"issue":"1\u20132","key":"6226_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, et al. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1\u20132):57\u201361.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 1","key":"6226_CR17","doi-asserted-by":"publisher","first-page":"i51","DOI":"10.1093\/eurheartjsupp\/suae104","volume":"27","author":"M Pieroni","year":"2025","unstructured":"Pieroni M, et al. Cardiac involvement in Fabry disease: Recent advances. Eur Heart J Suppl. 2025;27(Suppl 1):i51\u20135.","journal-title":"Eur Heart J Suppl"},{"issue":"1","key":"6226_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s44325-025-00058-6","volume":"2","author":"S Dougherty","year":"2025","unstructured":"Dougherty S, et al. Cardiac manifestations of Fabry disease. NPJ Cardiovasc Health. 2025;2(1):40.","journal-title":"NPJ Cardiovasc Health"},{"issue":"5","key":"6226_CR19","first-page":"e70008","volume":"66","author":"S Wanninayake","year":"2025","unstructured":"Wanninayake S, et al. The utility of high-sensitivity troponin to detect Fabry cardiomyopathy. JIMD Rep. 2025;66(5):e70008.","journal-title":"JIMD Rep"},{"issue":"1","key":"6226_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41525-025-00540-1","volume":"11","author":"T Wallraven","year":"2026","unstructured":"Wallraven T, et al. Endothelial dysfunction in Fabry disease: retinal microvascular assessment and inflammatory markers. NPJ Genom Med. 2026;11(1):6.","journal-title":"NPJ Genom Med"},{"key":"6226_CR21","doi-asserted-by":"publisher","first-page":"1867822","DOI":"10.3389\/fmed.2026.1867822","volume":"13","author":"S Wang","year":"2026","unstructured":"Wang S, et al. Pathogenic mechanisms in Fabry disease. Front Med. 2026;13:1867822.","journal-title":"Front Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06226-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06226-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06226-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:32:39Z","timestamp":1790922759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06226-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6226"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06226-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was submitted to and approved by the Ethics Committee of the University of Fortaleza (UNIFOR) (CAAE 58556021.5.0000.5052). All patients included in this study signed the Free and Informed Consent Form (TCLE), which was made available immediately after the invitation to participate in the research and followed the Brazilian law 466\/2012 and was according to the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there are no conflicts of interest regarding this paper. No direct conflicts of interest. Takeda Pharmaceuticals\u2019 support was unrelated to study design, analysis, writing, or publication decisions.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"865"}}